Bcal Diagnostics Ltd Secures $4.9M for FY2027 Cancer Test Commercialisation
BCAL locks in $4.9M funding to fuel FY2027 cancer detection push
BCAL Diagnostics (ASX: BDX) has secured firm commitments for an additional $4.9 million under its existing $10 million Convertible Note facility, originally announced on 20 October 2025. The additional funds will be drawn down as and when required.
The financing supports BCAL’s ongoing investment to develop and commercialise its blood-based early cancer detection portfolio through FY2027.
When big ASX news breaks, our subscribers know first
How the funding package breaks down
The funding announcement draws on two distinct sources. Alongside the Convertible Note commitments, BCAL expects to receive the first tranche of its FY2026 Research & Development tax offset claim.
-
Convertible Note facility: additional $4.9 million in firm commitments under the existing $10 million facility
-
FY2026 R&D Tax offset (first tranche): $1.4 million expected on or around 30 June 2026
-
This first tranche represents approximately 56% of BCAL’s expected FY26 R&D Tax offset of approximately $2.5 million
-
The balance of the tax offset is expected to be received in October 2026
According to the Company, the R&D Tax offset continues to be an important source of non-dilutive funding, meaning it does not require the issuance of new shares that would dilute existing holders.
| Funding Source | Amount | Timing | Type |
|---|---|---|---|
| Convertible Note (additional) | $4.9M | As required | Facility drawdown |
| R&D Tax offset (tranche 1) | $1.4M | ~30 Jun 2026 | Non-dilutive |
| R&D Tax offset (balance) | Balance | Oct 2026 | Non-dilutive |
The combined package is intended to fund BCAL’s planned activities through FY2027.
CEO Commentary
“We are delighted with the additional financing commitment for the balance of the Convertible Note facility. In addition, the R&D Tax offset continues to be an important source of non-dilutive funding for BCAL as we advance our early cancer detection portfolio. This funding supports our commercialisation strategy as we focus on making simple blood-based cancer tests more accessible to doctors and patients,” said Anne-Louise Arnett, Chief Executive Officer.
What blood-based early cancer detection means for investors
BCAL develops simple, non-invasive blood-based tests for early cancer detection. These tests offer an alternative or complement to traditional screening methods, with samples taken via a standard blood draw rather than more invasive procedures.
From a commercial standpoint, non-invasive blood tests can be more accessible for both doctors and patients, echoing the framing set out by management.
BCAL’s EarlyDetection platform, embedded in GP software covering approximately 97% of Australian practitioners, provides the referral infrastructure through which the blood-based tests this funding supports can reach patients without requiring clinicians to change existing workflows.
BCAL launched BREASTESTplus™ as a “rule-out” test designed for the clinical evaluation of breast disease in women with dense breasts. It is a simple, non-invasive blood test used in conjunction with mammography to support screening and diagnostic outcomes.
The Company also holds an exclusive license with ClearNote Health Inc., a US-based precision diagnostics company, for the sale and distribution of Avantect Pancreatic, Avantect Ovarian and Avantect multi-cancer blood tests in Australia and New Zealand.
The detection portfolio funding will advance
BCAL’s early detection portfolio that the secured funding supports includes:
-
BREASTESTplus
-
Avantect® Pancreatic
-
Avantect® Ovarian with BREASTESTplus Version 2
-
BREASTEST Monitor
-
Avantect® multi-cancer test (in development)
The Avantect® multi-cancer test remains in development and is not yet commercially available. The funding underpins continued commercialisation of this portfolio through FY2027, with a focus on making blood-based cancer tests more accessible to doctors and patients.
The BREASTEST Monitor, which achieved 91% sensitivity in preliminary findings and targets a global breast cancer surveillance market projected to reach $4.5 billion by 2030, represents one of the pipeline assets that continued FY2027 funding is intended to carry toward commercial validation.
The next major ASX story will hit our subscribers first
What’s next for BCAL
The secured funds are intended to support BCAL’s planned activities through FY2027. The balance of the R&D Tax offset, expected in October 2026, represents a near-term funding milestone for the Company.
With the additional Convertible Note commitments and the non-dilutive tax offset in place, BCAL has positioned its balance sheet to advance its commercialisation strategy across its early cancer detection portfolio.
Don’t Miss the Next Healthcare Breakthrough
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ investors already getting the edge on market-moving announcements the moment they drop. Click the “Free Alerts” button at StockWire X to start receiving alerts today.